Kristian Unger

Kristian Unger

Auto-generated profile, based on publicly available information

Kristian Unger

Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, 85764 Neuherberg, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Cancer Cell
Verified
Journal Article
Closed access
MWMonika Julia Wolf
Monika Julia Wolf
AAArlind Adili
Arlind Adili
KPKira Piotrowitz
Kira Piotrowitz
ZAZeinab Abdullah
Zeinab Abdullah
YBYannick Boege
Yannick Boege
MHMathias Heikenwälder
Mathias Heikenwälder

1 December 2015 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SFShlomi Finkin
Shlomi Finkin
DYDetian Yuan
Detian Yuan
ISIlan Stein
Ilan Stein
KTKoji Taniguchi
Koji Taniguchi
AWAchim Weber
Achim Weber
EPEli Pikarsky
Eli Pikarsky
Ectopic lymphoid structures develop at sites of chronic inflammation and are generally thought to be beneficial in the control of cancer. Pikarsky and colleagues show that these structures can instead nurture liver tumor progenitor cells. Ectopic lymphoid-like structures (ELSs) are often observed in cancer, yet their function is obscure. Although ELSs signify good prognosis in certain malignancies, we found that hepatic ELSs indicated poor prognosis for hepatocellular carcinoma (HCC). We studied an HCC mouse model that displayed abundant ELSs and found that they constituted immunopathological microniches wherein malignant hepatocyte progenitor cells appeared and thrived in a complex cellular and cytokine milieu until gaining self-sufficiency. The egress of progenitor cells and tumor formation were associated with the autocrine production of cytokines previously provided by the niche. ELSs developed via cooperation between the innate immune system and adaptive immune system, an event facilitated by activation of the transcription factor NF-κB and abolished by depletion of T cells. Such aberrant immunological foci might represent new targets for cancer therapy.

24 January 2018 in Nature
Verified
Journal Article
Closed access
PDF file
SMSebastian Mueller
Sebastian Mueller
TEThomas Engleitner
Thomas Engleitner
RMRoman Maresch
Roman Maresch
MZMagdalena Zukowska
Magdalena Zukowska
SLSebastian Lange
Sebastian Lange
RRRoland Rad
Roland Rad

8 September 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
XMXueru Mu
Xueru Mu
RERegina Español-Suñer
Regina Español-Suñer
IMIngmar Mederacke
Ingmar Mederacke
SASilvia Affò
Silvia Affò
RMRita Manco
Rita Manco
RSRobert F. Schwabe
Robert F. Schwabe
In many organs, including the intestine and skin, cancers originate from cells of the stem or progenitor compartment. Despite its nomenclature, the cellular origin of hepatocellular carcinoma (HCC) remains elusive. In contrast to most organs, the liver lacks a defined stem cell population for organ maintenance. Previous studies suggest that both hepatocytes and facultative progenitor cells within the biliary compartment are capable of generating HCC. As HCCs with a progenitor signature carry a worse prognosis, understanding the origin of HCC is of clinical relevance. Here, we used complementary fate-tracing approaches to label the progenitor/biliary compartment and hepatocytes in murine hepatocarcinogenesis. In genotoxic and genetic models, HCCs arose exclusively from hepatocytes but never from the progenitor/biliary compartment. Cytokeratin 19–, A6- and α-fetoprotein–positive cells within tumors were hepatocyte derived. In summary, hepatocytes represent the cell of origin for HCC in mice, and a progenitor signature does not reflect progenitor origin, but dedifferentiation of hepatocyte-derived tumor cells.

1 June 2017 in Cancer Cell
Verified
Journal Article
Closed access
DYDetian Yuan
Detian Yuan
SHShan Huang
Shan Huang
EBEmanuel Berger
Emanuel Berger
LLLei Liu
Lei Liu
NGNina Gross
Nina Gross
MHMathias Heikenwälder
Mathias Heikenwälder

27 October 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JWJulia Weber
Julia Weber
RÖRupert Öllinger
Rupert Öllinger
MFMathias Friedrich
Mathias Friedrich
UEUrsula Ehmer
Ursula Ehmer
MBMaxim Barenboim
Maxim Barenboim
RRRoland Rad
Roland Rad
Here, we show CRISPR/Cas9-based targeted somatic multiplex-mutagenesis and its application for high-throughput analysis of gene function in mice. Using hepatic single guide RNA (sgRNA) delivery, we targeted large gene sets to induce hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). We observed Darwinian selection of target genes, which suppress tumorigenesis in the respective cellular/tissue context, such as Pten or Cdkn2a, and conversely found low frequency of Brca1/2 alterations, explaining mutational spectra in human ICC/HCC. Our studies show that multiplexed CRISPR/Cas9 can be used for recessive genetic screening or high-throughput cancer gene validation in mice. The analysis of CRISPR/Cas9-induced tumors provided support for a major role of chromatin modifiers in hepatobiliary tumorigenesis, including that of ARID family proteins, which have recently been reported to be mutated in ICC/HCC. We have also comprehensively characterized the frequency and size of chromosomal alterations induced by combinatorial sgRNA delivery and describe related limitations of CRISPR/Cas9 multiplexing, as well as opportunities for chromosome engineering in the context of hepatobiliary tumorigenesis. Our study describes novel approaches to model and study cancer in a high-throughput multiplexed format that will facilitate the functional annotation of cancer genomes. Significance Assigning biological relevance and molecular function to large catalogues of mutated genes in cancer is a major challenge. Likewise, pinpointing drivers among thousands of transcriptionally or epigenetically dysregulated genes within a cancer is complex and limited by the lack of tools for high-throughput functional cancer genomic analyses. We show here for the first time, to our knowledge, application of the CRISPR/Cas9 genome engineering system for simultaneous (multiplexed) mutagenesis of large gene sets in adult mice, allowing high-throughput discovery and validation of cancer genes. We characterized applications of CRISPR/Cas9 multiplexing, resulting tumor phenotypes, and limitations of the methodology. By using defined genetic or environmental predisposing conditions, we also developed, to our knowledge, the first mouse models of CRISPR/Cas9-induced hepatocellular carcinoma and show how multiplexed CRISPR/Cas9 can facilitate functional genomic analyses of hepatobiliary cancers.